Company Profile
Forte Biosciences Stock Price, News & Catalysts
- Ticker:
- FBRX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
76.99 USD (+0.03%)
Close
Last updated: August 26, 2026
372M USD
Market cap
Why the stock is moving
Current closing-price context is not available for FBRX.
Company overview
Autoimmune Disease Drug Developer
Forte Biosciences develops therapies for autoimmune and inflammatory diseases. Its lead candidate targets a cytokine-receptor pathway involved in the activation and survival of pathogenic immune cells.
FB102 Anti-CD122 Antibody
FB102 is a monoclonal antibody targeting CD122, a receptor subunit shared by interleukin-2 and interleukin-15 signaling. The program is designed to modulate immune-cell populations implicated in multiple autoimmune diseases.
Celiac Disease Program
The company is evaluating FB102 in a Phase 2 study in celiac disease. The trial tests whether blocking CD122 can reduce the immune response and intestinal injury triggered by gluten exposure.
Alopecia Areata and Vitiligo
Early clinical studies are assessing FB102 in alopecia areata and vitiligo, diseases in which cytotoxic and memory immune cells contribute to tissue damage. Positive signals across these indications could support broader development of the mechanism.
Multi-Indication Development Strategy
Forte uses small proof-of-concept studies to evaluate the same biologic across distinct autoimmune conditions. This approach can identify the indications with the clearest efficacy signal before committing to larger trials.
Future catalysts
- Topline data from the Phase 2 celiac disease study and Phase 1b alopecia areata study of FB102 in the second half of 2026.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Forte Biosciences (FBRX)?
Forte Biosciences (FBRX) most recently closed at 76.99 USD, a +0.03% move versus the previous session.
What is the market cap of Forte Biosciences (FBRX)?
Forte Biosciences currently has a market capitalization of 372M USD on BioPharmSignal.
What does Forte Biosciences do?
Autoimmune Disease Drug Developer Forte Biosciences develops therapies for autoimmune and inflammatory diseases. Its lead candidate targets a cytokine-receptor pathway involved in the activation and survival of pathogenic immune cells. FB102 Anti-CD122 Antibody FB102 is a monoclonal antibody targeting CD122, a receptor subunit shared by interleukin-2 and...
On which exchange is FBRX stock listed?
Forte Biosciences (FBRX) is associated with NASDAQ, United States, Biopharma.
What is proof-of-concept?
Multi-Indication Development Strategy Forte uses small proof-of-concept studies to evaluate the same biologic across distinct autoimmune conditions.
Which conditions is Forte Biosciences targeting with proof-of-concept?
Autoimmune Disease Drug Developer Forte Biosciences develops therapies for autoimmune and inflammatory diseases. Its lead candidate targets a cytokine-receptor pathway involved in the activation and survival of pathogenic immune cells. FB102 Anti-CD122 Antibody FB102 is a monoclonal antibody targeting CD122, a receptor subunit shared by interleukin-2 and...
How does Forte Biosciences describe recent progress with proof-of-concept?
Topline data from the Phase 2 celiac disease study and Phase 1b alopecia areata study of FB102 in the second half of 2026.
What is Autoimmune?
Autoimmune Disease Drug Developer Forte Biosciences develops therapies for autoimmune and inflammatory diseases.